10x Genomics (TXG) Receivables (2018 - 2025)
Historic Receivables for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $82.5 million.
- 10x Genomics' Receivables fell 675.39% to $82.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $82.5 million, marking a year-over-year decrease of 675.39%. This contributed to the annual value of $82.5 million for FY2025, which is 675.39% down from last year.
- Latest data reveals that 10x Genomics reported Receivables of $82.5 million as of Q4 2025, which was down 675.39% from $96.6 million recorded in Q3 2025.
- 10x Genomics' 5-year Receivables high stood at $119.1 million for Q2 2025, and its period low was $52.5 million during Q1 2025.
- In the last 5 years, 10x Genomics' Receivables had a median value of $84.4 million in 2021 and averaged $85.5 million.
- As far as peak fluctuations go, 10x Genomics' Receivables soared by 16260.67% in 2021, and later crashed by 4244.67% in 2025.
- Quarter analysis of 5 years shows 10x Genomics' Receivables stood at $85.3 million in 2021, then rose by 22.24% to $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then fell by 22.96% to $88.5 million in 2024, then fell by 6.75% to $82.5 million in 2025.
- Its Receivables stands at $82.5 million for Q4 2025, versus $96.6 million for Q3 2025 and $119.1 million for Q2 2025.